Fluoroquinolone News and Research

RSS

Fluoroquinolone is a type of drug used to prevent and treat infections. Fluoroquinolones are associated with an increased risk of tendinitis and tendon rupture. This risk is further increased in those over age 60, in kidney, heart, and lung transplant recipients, and with use of concomitant steroid therapy.

Two-drug combination may alleviate radiation sickness in people

A combination of two drugs may alleviate radiation sickness in people who have been exposed to high levels of radiation, even when the therapy is given a day after the exposure occurred, according to a study led by scientists from Dana-Farber Cancer Institute and Children's Hospital Boston.

24 Nov 2011

NIAID's ACTG and TB Alliance partner to complete moxifloxacin Phase III trial

The TB Alliance announces the launch of a collaboration with the National Institute of Allergy and Infectious Diseases' (NIAID) AIDS Clinical Trial Group (ACTG) to conduct and help complete a Phase III clinical trial testing potentially faster-acting tuberculosis (TB) treatments.

16 Nov 2011

Furiex announces publications and presentations about antibacterial drug JNJ-Q2

Furiex Pharmaceuticals, Inc. today announced recent and upcoming publications and presentations about the novel investigational antibacterial drug JNJ-Q2.

12 Oct 2011

EMA CHMP adopts positive opinion for Optimer's DIFICLIR to treat C. difficile infection

Optimer Pharmaceuticals, Inc. today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion for DIFICLIR (fidaxomicin) tablets for the treatment of adults suffering with a Clostridium difficile infection (CDI), also known as C. difficile-associated diarrhea.

26 Sep 2011

Antibiotic-resistant Salmonella worries experts

According to an international team of researchers a strain of Salmonella that is resistant to important antibiotics has spread from Africa to Europe in recent years and has been spotted in a few samples of imported spices in the United States.

4 Aug 2011

Optimer introduces DIFICID for treatment of C. difficile-associated diarrhea

Optimer Pharmaceuticals, Inc. today announced the commercial launch of DIFICID (fidaxomicin) tablets for the treatment of Clostridium difficile-associated diarrhea (CDAD) in patients 18 years of age and older.

19 Jul 2011

Two DIFICID Phase 3 trial data in C. difficile infection presented at AGS Annual Meeting

Optimer Pharmaceuticals today announced the presentation of an additional analysis of data from the company's two Phase 3 clinical trials of DIFICID, an investigational antibiotic for the treatment of Clostridium difficile Infection, at the American Geriatric Society (AGS) Annual Meeting held in National Harbor, Maryland.

13 May 2011

Two DIFICID Phase 3 trial data in C. difficile presented at DDW conference

Optimer Pharmaceuticals, Inc. today announced the presentation of two abstracts at the 2011 Digestive Disease Week conference highlighting additional analyses of data from Phase 3 trials of DIFICID, an investigational product for the treatment of Clostridium difficile infection.

11 May 2011

Two DIFICID Phase 3 study data in C. difficile presented at ECCMID conference

Optimer Pharmaceuticals, Inc. today announced the presentation of two abstracts at the 21st European Congress of Clinical Microbiology and Infectious Diseases conference in Milan, Italy highlighting additional analyses of the Phase 3 data of DIFICID for the treatment of Clostridium difficile infection.

11 May 2011

Furiex Pharmaceuticals to present two JNJ-Q2 antibiotic abstracts at ECCMID/ ICC congress

Furiex Pharmaceuticals, Inc. today announced that two abstracts featuring its antibiotic candidate JNJ-Q2 will be presented at the 2011 joint meeting of the European Congress of Clinical Microbiology and Infectious Diseases and the International Congress of Chemotherapy.

6 May 2011

Furiex acquires full rights to JNJ-Q2, a novel broad-spectrum fluoroquinolone antibiotic

Furiex Pharmaceuticals, Inc. announced today that it has acquired full exclusive license rights to develop and commercialize the compound JNJ-Q2 under its existing development and license agreement with Janssen Pharmaceutica N.V.. Furiex acquired these rights as a result of Janssen's decision not to exercise its option under the agreement that gave Janssen the opportunity to continue development of JNJ-Q2.

20 Apr 2011

Optimer, Cubist sign deal to market DIFICID for CDI treatment in the U.S.

Optimer Pharmaceuticals, Inc. and Cubist Pharmaceuticals, Inc. today announced the signing of an exclusive two-year co-promotion agreement to market DIFICID, in the United States.

6 Apr 2011

Optimer study highlights economic burden of acute and recurrent CDI in hospital patients

Optimer Pharmaceuticals, Inc. announced today the presentation of information from insurance claims and survey databases highlighting the unmet need for targeted therapies to treat subpopulations at high risk of recurrence of Clostridium difficile infection.

4 Apr 2011

Optimer reports grant of inducement stock options

Optimer Pharmaceuticals, Inc. announced today that on March 31, 2011 the Compensation Committee of its Board of Directors approved the grant of inducement stock options to purchase an aggregate of 258,000 shares of common stock to 7 new employees.

2 Apr 2011

Optimer receives U.S. patent for fidaxomicin to treat CDI

Optimer Pharmaceuticals, Inc. announced today that the United States Patent and Trademark Office has issued U.S. Patent 7,906,489 which covers methods of Clostridium difficile infection treatment with fidaxomicin.

16 Mar 2011

Optimer prices underwritten public offering of common stock

Optimer Pharmaceuticals, Inc. today announced the pricing of a previously announced underwritten public offering of 6,000,000 shares of its common stock, offered at a price to the public of $11.25 per share. The gross proceeds to Optimer from this offering are expected to be $67.5 million, before deducting the underwriting discounts and commissions and other estimated offering expenses payable by Optimer.

11 Feb 2011

Rib-X commences Phase 2b trial to assess delafloxacin, linezolid, vancomycin for treatment of ABSSSI

Rib-X Pharmaceuticals, an antibiotics company with a broad development-stage pipeline, today announced the initiation of a Phase 2b clinical trial to evaluate delafloxacin, linezolid and vancomycin for the treatment of acute bacterial skin and skin structure infections, including infections caused by methicillin-resistant Staphylococcus aureus.

8 Feb 2011

New England Journal publishes fidaxomicin Phase 3 trial results against CDI

Optimer Pharmaceuticals, announced The New England Journal of Medicine has published results from the North American Phase 3 trial evaluating the safety and efficacy of the Company's novel antibiotic fidaxomicin as a treatment for patients with Clostridium difficile infection.

3 Feb 2011

FDA accepts Optimer's fidaxomicin NDA for filing

Optimer Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) has accepted for filing the Company's New Drug Application (NDA) for fidaxomicin for the treatment of Clostridium difficile infection (CDI) and for reducing the risk of recurrence when used for treatment of initial CDI.

24 Jan 2011

Rib-X raises $20M to support development of broad spectrum antibiotics pipeline

Rib-X Pharmaceuticals, Inc. today announced that the Company has raised $20 million to support ongoing development of the Company's industry-leading broad spectrum antibiotics pipeline, including late-stage clinical development of delafloxacin, which is expected to enter a Phase 2b study in early 2011.

11 Jan 2011